Previous 10 | Next 10 |
2024-02-15 14:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-- Activation of four U.S. sites for Phase 1 clinical trial of PAS-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- Plans to open three additional sites in Eastern Europe in the coming months -- -- Preliminary interim data expected in 2H 2024 -- SOUTH SA...
Verde Clean Fuels Inc. (VGAS) is expected to report for Q4 2023 Pioneer Bancorp Inc. (PBFS) is expected to report for Q2 2024 Equity Commonwealth of Beneficial Interest (EQC) is expected to report $0.27 for Q4 2023 monday.com Ltd. (MNDY) is expected to report $-0.31 for Q4 2023 As...
Pasithea Therapeutics Corp. (KTTA) is expected to report for Q4 2023
2024-02-05 01:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-25 10:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-- Polymorph and Stereoisomer Patents when Issued Extend Portfolio to at least 2045 -- -- Polymorph and Stereoisomer Patent Filings Continue to Expand Patent Portfolio -- SOUTH SAN FRANCISCO, Calif. and MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ...
2024-01-02 09:11:26 ET More on Pasithea Therapeutics Pasithea stock soars as high as 190% on preclinical data Pasithea stock jumps 12% on update for anti-tumor drug PAS-004 Financial information for Pasithea Therapeutics For further details see: Pasithea ...
-- PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials -- -- Phase 1 dose escalation study in patients with MAPK pathway driven advanced solid tumors to begin in Q1 2024 – -- Initial readout expected as early as Q3 2024 – SOUTH SAN FRANCISCO, ...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today announced that its meeting of stockholders, which had been partially adjourned on December 19, 2023, was reconvened o...
News, Short Squeeze, Breakout and More Instantly...
Pasithea Therapeutics Corp. Company Name:
KTTA Stock Symbol:
NASDAQ Market:
SOUTH SAN FRANCISCO, Calif. and MIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the tr...
SOUTH SAN FRANCISCO, Calif. and MIAMI, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the ...
2024-04-16 18:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...